Abstracts tagged "Bone density"

Abstract Number: 1352 • ACR Convergence 2025
Prediction of 5-Year Fracture Risk in Rheumatoid and Psoriatic Arthritis Using REMS Technology
Marco Di Paola¹, Edmund J MacLaughlin², Kathleen Methric³, Maurizio Muratore⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Ernesto Casciaro¹, Fabiola Rosa Contaldo⁷, Fiorella Anna Lombardi¹, Paola Pisani¹, Francesco Conversano¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³BoneVue Diagnostics, Catonsville, MD, ⁴ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Environmental Sciences and Technologies, University of Salento, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Autoimmune arthritis, including Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PA), are among the most common forms of inflammatory joint diseases. These conditions affect joints…
Abstract Number: 2592 • ACR Convergence 2025
Romosozumab and Denosumab Combination Therapy in Postmenopausal Osteoporosis
Giovanni Adami¹, Francesco Pollastri², Angelo Fassio², Camilla Benini², Davide Gatti², Ombretta Viapiana² and Maurizio Rossini², ¹University of Verona, Italy, Verona, Italy, ²University of Verona, Verona, Italy
Background/Purpose: Transition from long-term denosumab to PTH-analogs or romosozumab might expose patients to the risk of the so-called rebound phenomenon. Adding romosozumab to denosumab might…
Abstract Number: 0452 • ACR Convergence 2025
Ten-Year Real-World Longitudinal Analysis of Bone Mineral Density in Rheumatoid Arthritis: Impact of RA and Osteoporosis Treatments
Keigo Hayashi¹, Kei Hirose², Natsuki Kubota¹, Yuya Terajima¹, Kazuya Matsumoto¹, Takato Nakadoi¹, Shoichi Nawachi¹, Yoshia Miyawaki³, Eri Katsuyama⁴, Takayuki Katsuyama¹, Haruki Watanabe¹, Mariko Narazaki¹, Yoshinori Matsumoto¹ and Jun Wada¹, ¹Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁴Faculty of Health Science, Okayama University Medical School, Graduate School of Health Sciences, Boston, MA
Background/Purpose: Despite advancements in rheumatoid arthritis (RA) and osteoporosis management that have improved patient outcomes, osteoporosis continues to be a significant clinical concern in RA.…
Abstract Number: 2501 • ACR Convergence 2025
Microvascular dysfunction contributes to hand bone deterioration in SSc patients
Rosanna Campitiello¹, Sabrina Paolino², Andrea Casabella³, Giulia Davoli², Elisa Caratto⁴, Emanuele Gotelli¹, Elvis Hysa⁵, Carmen Pizzorni², Vanessa Smith⁶, Alberto Sulli² and Maurizio Cutolo⁷, ¹University of Genoa, Genoa, Liguria, Italy, ²University of Genoa, Genova, Italy, ³IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁴Univeristy of Genoa, Alessandria, Italy, ⁵University of Genoa, Genoa, Italy, ⁶Ghent University Hospital, Gent, Belgium, ⁷University of Genova, Genova, Italy
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by endothelial dysfunction, self-reactive immune response and progressive systemic fibrosis1. It is well established that…
Abstract Number: 0355 • ACR Convergence 2025
Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy
Soukayna Baddi¹, Suarez Dimitri¹, Alexis Ruet¹, Theo Van Butsel¹, Damiano Cerasuolo¹, Jean-Matthieu L’Orphelin¹ and Anne-Christine Rat², ¹Caen University Hospital, Caen, France, ²Caen University hospital, UMR ¹⁰⁷⁵ Caen normandy university, Caen, France
Background/Purpose: The use of immune checkpoint inhibitors (ICIs) is becoming increasingly important in the management of melanoma. However, although ICIs are associated with various immune-related…
Abstract Number: 2479 • ACR Convergence 2025
REMS technology 5-y Imminent Fracture Risk in Systemic Sclerosis.
Fiorella Anna Lombardi¹, Edmund J MacLaughlin², Marco Di Paola¹, Maurizio Muratore³, Kathleen Methric⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Ernesto Casciaro¹, Andrea Claudio Ştețco⁷, Francesco Conversano¹, Paola Pisani¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁴BoneVue Diagnostics, Catonsville, MD, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Systemic sclerosis (SS) is a rare connective tissue disorder characterized by progressive fibrosis of the skin and internal organs, including lungs, heart and kidneys.…
Abstract Number: 0351 • ACR Convergence 2025
Experience with romosozumab in women with osteoporosis at high risk of fracture in real-world clinical practice
MARIA DEL CARMEN ORTEGA DE LA O¹, Laura Gonzalez Hombrado², Marina Salido Olivares³, Carolina Marin⁴, Angel Aragon⁵, Celia arconada⁶, Maria Carmen Ortega de la O⁷, Alvaro Garcia⁸, elisabeth Castañeda⁹, Patricia Castro Perez¹⁰, alberto diaz Oca¹¹ and Eva Andres Esteban¹², ¹HOSPITAL UNIVERSITARIO GETAFE, GETAFE, Madrid, Spain, ²Hospital Universitario del Tajo, Aranjuez (MADRID), Madrid, Spain, ³Hospital Clinico San Carlos, Madrid, Madrid, Spain, ⁴Hospital Infanta Leonor, Madrid, Madrid, Spain, ⁵Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain, ⁶Hospital universitario de Getafe, Getafe, Madrid, Spain, ⁷Hospital Universitario Getafe, Madrid, Madrid, Spain, ⁸Hospital Universitario del Tajo, Aranjuez, Madrid, Spain, ⁹Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ¹⁰Hospital de Getafe, Madrid, Madrid, Spain, ¹¹Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain, ¹²Universidad Rey Juan Carlos, Fuenlabrada, Spain
Background/Purpose: Romosozumab (RMZ) is a recently approved dual-acting drug which has been shown to reduce fracture risk in patients with osteoporosis (OP) in clinical trials.…
Abstract Number: 2244 • ACR Convergence 2025
Bone Mineral Density Trajectories and Fracture Risk in Rheumatoid Arthritis: A 7-Year Longitudinal Analysis Using Group-Based Trajectory Modeling
Kei Hirose¹, Keigo Hayashi², Natsuki Kubota², Yuya Terajima², Kazuya Matsumoto², Takato Nakadoi², Shoichi Nawachi², Yoshia Miyawaki³, Eri Katsuyama⁴, Takayuki Katsuyama², Haruki Watanabe², Mariko Narazaki², Yoshinori Matsumoto² and Jun Wada², ¹Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁴Faculty of Health Science, Okayama University Medical School, Graduate School of Health Sciences, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a well-established risk factor for fractures, due to both systemic inflammation and treatment-related effects on bone metabolism. This study aimed…
Abstract Number: 0349 • ACR Convergence 2025
Underrecognized Glucocorticoid-Induced Osteoporosis in a Polymyalgia Rheumatica Patient Cohort
katherine Loomba¹, Emily Campbell¹, Nisha Khubchandani¹, chih Fang¹, William Rigby² and Vivekanand Tiwari¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth-Hitchcock, Norwich, VT
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are systemic inflammatory disorders treated with prolonged corticosteroid therapy. Prolonged use of corticosteroids is a significant…
Abstract Number: 2123 • ACR Convergence 2025
Sclerostin in Aging Bone and Muscle: A Comparative Study of Osteoporosis, Sarcopenia, and Osteosarcopenia
Mohamed Tharwat Hegazy¹, Fatma Fayed¹, Shirihan Mahgoub¹, Yasmin El Ebrashy² and Maha Hossam Al-Din Ibrahim¹, ¹Faculty of Medicine, Cairo University, Cairo, Egypt, ²National institute of Diabetes and Endocrinology, Cairo, Egypt
Background/Purpose: Osteoporosis, sarcopenia, and frailty are the 3 determinants of aging. A novel syndrome of combined osteosarcopenia has negative health outcomes among geriatric populations. In…
Abstract Number: 0348 • ACR Convergence 2025
Correlation between Bone Mineral Density by Dual-energy X-ray Absorptiometry at the Radius and Radius Cortical Bone Thickness using Routine Hand Radiographs in Rheumatoid Arthritis Patients
Karla Miller¹, Amani Jridi² and Tina Basak³, ¹University of Utah School of Medicine, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah Department of Radiology, Salt Lake City, UT
Background/Purpose: Rheumatoid arthritis (RA) patients are at higher risk of having generalized osteoporosis of the axial and appendicular skeleton assessed by dual-energy x-ray absorptiometry (DXA)…
Abstract Number: 2122 • ACR Convergence 2025
Safety and Efficacy of Romosozumab in the Treatment of Patients with High-Risk Fracture Osteoporosis in Clinical Practice: Experience from a Tertiary University Hospital in Spain
Maryia Nikitsina¹, Cristina Valero², Miren Uriarte Ecenarro³, Ana M Ortiz³, María Ahijón Lana³, Irene Llorente³, Marina Dueñas-Ochoa⁴, Juan C Saez⁵, EVA GLORIA TOMERO MURIEL⁶, Esther Vicente-Rabaneda⁶, Isidoro Gonzalez-Alvaro⁷, Rosario Garcia Vicuña⁶ and Santos Castañeda⁸, ¹University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, ²Hospital de la Princesa, Madrid, Spain, ³Hospital Universitario La Princesa, Madrid, Spain, ⁴Hospital La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Madrid, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷Department of Rheumatology, Hospital Universitario La Princesa, IIS, Madrid Spain, Madrid, Spain, ⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Romosozumab (RSZ) is a dual osteoanabolic agent that stimulates bone formation and reduces bone resorption, emerging as a promising option for treating osteoporosis (OP)…
Abstract Number: 0347 • ACR Convergence 2025
Identifying Risk Factors for Fragility Fractures in Patients with Coeliac Disease: An Observational Study
Kabyar Cho¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe Bay NHS Foundation Trust, Barrow-In-Furness, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Coeliac disease (CD) is an autoimmune disease, which has been widely reported to be associated with reduced bone mineral density (BMD), leading to an…
Abstract Number: 2119 • ACR Convergence 2025
Fracture rates in 6475 individuals with osteogenesis imperfecta stratified by age, sex and clinical severity
Winnie Liu¹, Jeffrey Curtis², Lars Folkestad³, Emily Holladay⁴, Jingyi zhang², Shanette Daigle⁵, Ye Liu², Fenglong Xie⁶ and Eric Orwoll¹, ¹Oregon Health and Science University, Portland, OR, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Southern Denmark, Odense, Denmark, Odense, Denmark, ⁴Foundation for Advancing Science Technology Education and Research, Hoover, AL, ⁵Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ⁶The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by bone fragility caused by mutations related to type 1 collagen biosynthesis. Fractures are a…
Abstract Number: 0346 • ACR Convergence 2025
Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk
José Rodríguez gago¹, Carolina Tornero², Lina León³, María Luisa González-Casaus³, Luisa Fernanda Giraldo³, Gloria del Peso³, Diego Garrido³, Teresa López³, Mónica Coronado³, María Auxiliadora Bajo⁴, Sara García³, María Gema Serrano³, Marta Ossorio³, Alejandro Balsa³ and Pilar Aguado³, ¹Hospital Universitario La Paz, MADRID, ²Hospital La Paz, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Hospital Universitario de la Princesa - ISS Princesa, Madrid, Spain
Background/Purpose: Chronic kidney disease (CKD) is linked to increased vascular comorbidity and fracture risk. This study aims to assess bone status in CKD patients versus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].